Dr Rahul Kushwah on how Predictmedix’s AI driven Safe Entry Station detects disease and impairment symptoms
In a recent InvestorIntel interview, Tracy Weslosky speaks with Dr. Rahul Kushwah, Co-Founder and COO of Predictmedix Inc. (CSE: PMED | OTCQB: PMEDF) about Predictmedix’s artificial intelligence powered infectious disease symptom screening solution for workplace health and safety.
In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Dr. Kushwah went on to say, “You can open facilities and workplaces but it is about bringing in technologies that can create safety bubbles in those places. That is where our infectious disease symptom screening solution or Safe Entry Station comes into play. The technology can identify a host of symptoms associated with COVID-19.”
Speaking on the competitive advantages of Predictmedix’s Safe Entry Station Dr. Kushwah said, “It looks at several symptoms associated with infectious diseases. So, it is not just another fever scanner. At the same time, there is a deep learning algorithm that runs in the background. As more and more people pass through the system the system keeps on getting smarter.”
To watch the full interview, click here
About Predictmedix Inc.
Predictmedix Inc. is an artificial intelligence (“AI”) company developing disruptive tools for impairment testing and healthcare. It is intended that the Company’s cannabis and alcohol impairment detection tools will be used across various workplaces and by law enforcement agents. Its technology uses facial and voice recognition to identify both cannabis and alcohol impairment by utilizing multiple features along with numerous different data points. Testing does not require any body fluids or human intervention, thereby helping to remove human error and the potential for discrimination and prejudice.
The Company is also developing AI based screening for the healthcare industry. The recent advent of COVID-19 pandemic has placed unprecedented stress on the global economy and highlights the need for tools to help screen mass populations for infectious diseases, with the hope of preventing pandemics in the future. In turn, Predictmedix Inc. is expanding its proprietary AI technology to screen for infectious disease symptoms.
Additionally, psychiatric disorders such as depression, dementia and Alzheimer’s disease can carry a significant burden and early identification is the key to better management. To help address this, the Company is also expanding its proprietary AI technology to screen for psychiatric and/or brain disorders such as depression, dementia and Alzheimer’s disease.
To learn more about Predictmedix Inc., click here
Disclaimer: Predictmedix Inc. is an advertorial member of InvestorIntel Corp.